• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Essential Thrombocythemia - Pipeline Review, H2 2012 Product Image

Essential Thrombocythemia - Pipeline Review, H2 2012

  • ID: 2216741
  • July 2012
  • 81 pages
  • Global Markets Direct

Essential Thrombocythemia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Essential Thrombocythemia - Pipeline Review, H2 2012', provides an overview of the Essential Thrombocythemia therapeutic pipeline. This report provides information on the therapeutic development for Essential Thrombocythemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Essential Thrombocythemia. 'Essential Thrombocythemia - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Essential Thrombocythemia.
- A review of the Essential Thrombocythemia products READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Essential Thrombocythemia Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Essential Thrombocythemia 9
Essential Thrombocythemia Therapeutics under Development by Companies 11
Essential Thrombocythemia Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Essential Thrombocythemia Therapeutics – Products under Development by Companies 16
Essential Thrombocythemia Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Essential Thrombocythemia Therapeutics Development 18
Sanofi-Aventis 18
AstraZeneca PLC 19
Eli Lilly and Company 20
Gilead Sciences, Inc. 21
YM BioSciences Inc. 22
Novartis AG 23
Incyte Corporation 24
Geron Corporation 25
Aop Orphan Pharmaceuticals AG 26
PharmaMar, S.A. 27
Essential Thrombocythemia – Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
AZD1480 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
GRN163L - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
LBH589 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CYT387 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Jakafi - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
SAR302503 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Aplidin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Clofarabine + Melphalan + Alemtuzumab + Stem Cell Transplantation - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Pomalidomide - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Cyclophosphamide + Busulfan + Methotrexate + Tacrolimus + Allogenice Hematopoietic Stem Cell Transplantation - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 48
Pegasys - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Dacogen - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
GS 6624 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Fludarabine Phosphate + Total-Body Irradiation + Peripheral Blood Stem Cell Transplantation + Cyclosporine + Mycophenolate Mofetil - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 54
CC-4047 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
LY2784544 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Pegasys + Aspirin - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Anagrelide Retard - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Essential Thrombocythemia Therapeutics – Drug Profile Updates 62
Essential Thrombocythemia Therapeutics – Discontinued Products 72
Essential Thrombocythemia – Product Development Milestones 73
Featured News & Press Releases 73
May 31, 2011: YM BioSciences Announces Orphan Drug Designation For JAK1/JAK2 Inhibitor CYT387 In Europe 73
Dec 06, 2010: Incyte Presents Positive Phase II Trial Results Of INCB18424 In Advanced Polycythemia Vera And Essential Thrombocythemia At ASH Annual Meeting 73
Mar 03, 2010: Geron Gives Five Presentations On Telomerase Inhibitor Imetelstat At The AACR Annual Meeting 75
May 28, 2009: Incyte Provides Update on Special Protocol Assessment for INCB18424 As A New Treatment for Myelofibrosis 77
Apr 18, 2005: IMPAX Receives Final FDA Approval for Generic Version Of Agrylin; Third Approval in 2005 77
Apr 18, 2005: Mylan Receives Approval for Anagrelide Hydrochloride Capsules 77
May 28, 2004: US-FDA grants Six months additional market exclusivity for AGRYLIN. 78
Feb 01, 2004: Shire's Agrylin licensed to Kirin pharmaceutical in Japan. 78
Dec 18, 2003: Agrylin is Outlicensed by Shire in Japan 78
Jun 08, 1999: Agrylin Receives Orphan Drug Status In Japan. 79
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 81
Disclaimer 81

List of Tables
Number of Products Under Development for Essential Thrombocythemia, H2 2012 9
Products under Development for Essential Thrombocythemia – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
Sanofi-Aventis, H2 2012 18
AstraZeneca PLC, H2 2012 19
Eli Lilly and Company, H2 2012 20
Gilead Sciences, Inc., H2 2012 21
YM BioSciences Inc., H2 2012 22
Novartis AG, H2 2012 23
Incyte Corporation, H2 2012 24
Geron Corporation, H2 2012 25
Aop Orphan Pharmaceuticals AG, H2 2012 26
PharmaMar, S.A., H2 2012 27
Assessment by Monotherapy Products, H2 2012 28
Assessment by Combination Products, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 33
Essential Thrombocythemia Therapeutics – Drug Profile Updates 62
Essential Thrombocythemia Therapeutics – Discontinued Products 72

List of Figures
Number of Products under Development for Essential Thrombocythemia, H2 2012 9
Products under Development for Essential Thrombocythemia – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 28
Assessment by Combination Products, H2 2012 29
Assessment by Route of Administration, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Molecule Type, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 33

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos